Standard Dosing of MIEBO (Perfluorohexyloctane)
Instill one drop of MIEBO four times daily into each affected eye. 1
Dosing Regimen
- Frequency: Four times daily (QID) administration 1, 2, 3
- Volume: One drop per affected eye with each administration 1
- Duration: Treatment is ongoing; efficacy and safety have been demonstrated for up to 52 weeks of continuous use 4
Administration Technique
The FDA-approved administration instructions require a specific technique to properly dispense this unique perfluorinated formulation 1:
- Remove the cap from the bottle 1
- Hold the bottle upright and gently squeeze it 1
- While squeezing, turn the bottle upside down and release pressure (this draws air into the bottle) 1
- Keep the bottle upside down, place it above your eye, and squeeze again to release a drop 1
- Repeat for the second affected eye if bilateral treatment is needed 1
Critical Timing Considerations with Contact Lenses
- Remove contact lenses prior to instillation 1
- Wait at least 30 minutes after administration before reinserting contact lenses 1
- This precaution is mandatory because MIEBO should not be administered while wearing contact lenses 1
Onset of Efficacy
- Significant improvements in dry eye symptoms can be observed as early as 2 weeks after initiating treatment 5, 2
- In clinical trials, meaningful reductions in symptom severity and frequency were documented by day 3 to day 7 of treatment 6
- Peak efficacy is typically achieved by week 8, with sustained benefits maintained through 52 weeks of continuous use 4, 3
Clinical Context
MIEBO is the first and only FDA-approved prescription treatment that directly addresses excessive tear evaporation by forming a monolayer at the air-liquid interface of the tear film 2. This mechanism is particularly relevant for patients with dry eye disease associated with meibomian gland dysfunction 3, 7. The four-times-daily dosing schedule was established in the pivotal GOBI and MOJAVE phase 3 trials and maintained in the year-long KALAHARI extension study 4, 3.